Latest Content

T-cell engagers and antibody-drug conjugates are expanding the SCLC treatment landscape as researchers focus on improving responses and overcoming resistance.

Rob Lowe joins CURE Talks Cancer to share his grandmother's breast cancer journey, including the clinical trial that helped prolong her life after she was twice told to get her affairs in order.

Karyopharm submitted an FDA application seeking accelerated approval for XPOVIO plus ruxolitinib for patients with myelofibrosis.

Tagrisso plus Orpathys improved progression-free survival in patients with EGFR-mutated lung cancer and MET overexpression, SANOVO trial shows.

A cancer survivor reflects on body image, grief and emotional healing 12 years after treatment, and why healing doesn’t have to be perfect to be real.

The A-NEW study found that 42% of breast cancer survivors with slower early weight loss reached the 5% goal after Contrave was added.

FDA approves BESREMi for adults with essential thrombocythemia, offering a new treatment option for people living with this rare blood cancer.

FDA approves Mimrylo (rusfertide) for adults with polycythemia vera, offering a new treatment approach that may reduce the need for frequent blood draws.

After breast cancer treatment ends, survivorship can bring unexpected challenges. One survivor shares how she learned to heal and redefine who she is.

Ivonescimab plus chemotherapy improved survival compared with Imfinzi plus chemotherapy in patients with previously untreated advanced biliary tract cancer, according to phase 3 findings.

A breast cancer survivor reflects on managing lymphedema, navigating Dupuytren’s disease and finding perspective when new health challenges arise.

Theresa Gannon’s compassion, leadership and dedication to patients and fellow oncology nurses make her an Extraordinary Healer Award nominee.

Dr. Maria Margarete Karsten discusses how weekly symptom monitoring helped identify changes between visits and what patients told her about using it.